For years, scientists have been talking about how digital breast tomosynthesis (DBT), a technique that enables radiologists to view three-dimensional images of the breast, is going to revolutionize breast screening. The development and approval process has taken much longer than anyone anticipated, but that hasn't dampened the enthusiasm of leading researchers, many of whom now believe that approval from the Food and Drug Administration (FDA) for at least one DBT system will come within the next year.